Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6556298 | 0.85 | GRIA4 (0.55) | GRIA4KMT2AMEN1ALDH1A1CA1 | |
| SCHEMBL6556147 | 0.83 | GRIA4 (0.52) | GRIA4KMT2AMEN1L3MBTL1HPGD | |
| SCHEMBL6554408 | 0.79 | GRIA4 (0.67) | GRIA4SMN1; SMN2LMNA | |
| SCHEMBL338392 | 0.79 | GRIA4 (0.67) | GRIA4SMN1; SMN2LMNA | |
| SCHEMBL6759326 | 0.79 | GRIA4 (0.67) | GRIA4SMN1; SMN2LMNA | |
| SCHEMBL6562902 | 0.79 | GRIA4 (0.53) | GRIA4L3MBTL1ALDH1A1CA1CA2 | |
| SCHEMBL20921363 | 0.78 | KMT2A (0.56) | KMT2AMEN1L3MBTL1HPGDCYP3A4 | |
| SCHEMBL18896279 | 0.77 | KMT2A (0.58) | KMT2AMEN1L3MBTL1HPGDALDH1A1 | |
| SCHEMBL6565123 | 0.77 | GRIA4 (0.68) | GRIA4 | |
| SCHEMBL6565191 | 0.75 | GRIA4 (0.50) | GRIA4KMT2AMEN1L3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | BLEAKMAN DAVID (US) | 2004-11-25 | — | — | US | disclosed |
| US-6803484-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20040143020-A1 | Sulfonamide derivatives | AIKINS JAMES ABRAHAM (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1438036-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6720357-B2 | TREATMENT OF CONDITIONS ASSOCIATED WITH GLUTAMATE HYPOFUNCTION, SUCH AS PSYCHIATRIC AND NEUROLOGICAL DISORDERS; N-2-(4-N-(3,5-DIFLUOROBENZAMIDO)PHENYL)PROPYL-2-PROPANESULFONAMIDE | ELI LILLY AND COMPANY | 2004-04-13 | — | — | US | disclosed |
| EP-1390072-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030233015-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | BENDER DAVID MICHAEL (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1309577-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2003032974-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-04-24 | — | — | WO | disclosed |
| EP-1296944-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002014294-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090056-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030233015-A1 | Sulfonamide derivatives | GRIN2A, GRIN1, SLC1A2 | GRIA4 14/4885KMT2A 597/4885MEN1 4032/4885 |
| US-20040143020-A1 | Sulfonamide derivatives | GRIN2A, GRIN2B, SLC1A2 | GRIA4 13/4885KMT2A 515/4885MEN1 4306/4885 |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | GABRE, SCN2A, SCN1A | GRIA4 212/4885KMT2A 664/4885MEN1 1630/4885 |
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | GRIN2A, GRIN2B, GRIN1 | GRIA4 12/4885KMT2A 915/4885MEN1 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.